We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
04 May 2021 - 07 May 2021
Virtual Venue

Mannose-Binding Lectin Associated with Coagulopathy in Severe COVID-19

By LabMedica International staff writers
Posted on 24 Sep 2020
Print article
Image: An enzyme-linked immunosorbent assay for mannose-binding lectin found that this molecule is associated with coagulopathy in severe COVID-19 patients (Photo courtesy of Getty Images).
Image: An enzyme-linked immunosorbent assay for mannose-binding lectin found that this molecule is associated with coagulopathy in severe COVID-19 patients (Photo courtesy of Getty Images).
The ongoing COVID-19 pandemic has caused significant morbidity and mortality worldwide, as well as profound effects on society. COVID-19 patients have an increased risk of thromboembolic (TE) complications, which develop despite pharmacological thromboprophylaxis.

The mechanism behind COVID-19-associated coagulopathy remains unclear. Mannose-binding lectin (MBL), a pattern recognition molecule that initiates the lectin pathway of complement activation, has been suggested as a potential amplifier of blood coagulation during thromboinflammation.

Immunologists at the Uppsala University (Uppsala, Sweden) and their colleagues clarify the role of MBL in COVID-19 and measured plasma MBL levels and activity in a cohort of 65 critically ill COVID-19 patients and investigated its relation to clinical outcome. All patients were over 18 years of age with confirmed or suspected COVID-19 admitted to the ICU between March 13 and April 30, 2020, were screened for inclusion.

Blood was sampled in ethylenediaminetetraacetic acid tubes, and plasma stored at –70 °C until analysis. Plasma MBL levels at day 1 at the ICU (on average COVID-19 day 10) were measured by an in-house enzyme-linked immunosorbent assay (ELISA), and were significantly higher than in healthy controls. Activity of the MBL pathway was assessed by a functional ELISA using mannan as activator and MBL binding capacity and complement C3 deposition as readouts. This assay measures the functional MBL concentration in plasma and its capacity to activate complement, and confirmed elevated MBL activity and MBL-dependent C3 deposition in the patient group.

The team reported that nine (14%) patients who developed symptomatic thromboembolism, despite receiving thromboprophylaxis, had significantly higher MBL levels than patients who did not experience a thromboembolic event (median 1,233 kU/L versus 470 kU/L). All patients in the study received thromboprophylaxis with either dalteparin sodium (n = 64) or apixaban (n = 1). Of the nine patients in the study who developed a symptomatic thromboembolic event during their time at the ICU, two were arterial thrombosis (stroke or myocardial infarction) and seven were pulmonary embolisms (PEs). COVID-19 patients have elevated plasma MBL levels compared with healthy controls: 625 kU/L in the patient group (n = 65) versus. 444 kU/L in the healthy blood donors controls (n = 72).

Interestingly, patients who developed PE all had MBL levels above the 95th percentile compared with controls. MBL showed a significant correlation with total complement factor C3 levels, but not with the activation product C3d (measured as C3d/C3 ratio), a measure of activity of the alternative pathway of complement, nor with C1q, the initiator of the classical pathway. Total C3 levels, C3d/C3 ratio, or C1q were not related to thrombotic events, indicating a specific association between MBL and thrombosis.

The authors concluded that they had identified complement activation through the MBL pathway as a novel amplification mechanism that contributes to pathological thrombosis in critically ill COVID-19 patients. Pharmacological targeting of the MBL pathway could be a novel treatment option for thrombosis in COVID-19. Laboratory testing of MBL levels could be of value for identifying COVID-19 patients at risk for thromboembolic events. The study was published on September 1 2020 in the journal Thrombosis and Haemostasis.

Related Links:
Uppsala University

Gold Supplier
COVID-19 Test
ID NOW COVID-19
New
Molecular Diagnostics Integrated System
SENTiNAT 200
New
Gold Supplier
SARS-CoV-2, Flu A/B, and RSV Test
SARS-CoV-2 PLUS ELITe MGB Kit
SARS-CoV-2 Antigen Test
ESPLINE SARS-CoV-2 Antigen Test

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Randox Discovery Diagnostic Analyzer Wins 2021 Red Dot Award for High Design Quality (Photo courtesy of Randox Laboratories)

Randox Discovery Diagnostic Analyzer Wins 2021 Red Dot Award for High Design Quality

Randox Laboratories’ (Crumlin, UK) Discovery, a diagnostic analyzer which can consolidate molecular and immunoassay testing on one compact benchtop platform, has received the 2021 Red Dot Award for High... Read more

Industry

view channel
Image: Eppendorf Centrifuge 5910 Ri (Photo courtesy of Eppendorf AG)

Eppendorf Introduces Multipurpose Centrifuge 5910 Ri to Accelerate Results

Eppendorf AG (Hamburg, Germany) has introduced a new centrifuge designed to increase efficiency in the laboratory, Centrifuge 5910 Ri, a successor to the company’s popular Centrifuge 5910 R.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.